| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S40265-017-0828-8 |
| P698 | PubMed publication ID | 29094312 |
| P50 | author | David Pace | Q80465561 |
| Sohita Dhillon | Q102146188 | ||
| P2860 | cites work | The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines | Q26741969 |
| Meningococcal serogroup Y emergence in Europe: update 2011 | Q28703551 | ||
| An epidemiological review of changes in meningococcal biology during the last 100 years | Q33850814 | ||
| Protein carriers of conjugate vaccines: characteristics, development, and clinical trials | Q34170021 | ||
| Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. | Q34537851 | ||
| Epidemic meningitis, meningococcaemia, and Neisseria meningitidis | Q34644525 | ||
| Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England | Q35923728 | ||
| Meningococcal surrogates of protection--serum bactericidal antibody activity | Q36065385 | ||
| Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children | Q36391874 | ||
| The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiorit | Q36391883 | ||
| The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults | Q36391888 | ||
| Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study | Q36781534 | ||
| Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial | Q36791713 | ||
| Description and nomenclature of Neisseria meningitidis capsule locus | Q36825126 | ||
| Systematic review: Impact of meningococcal vaccination on pharyngeal carriage of meningococci | Q36981703 | ||
| Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine | Q37130274 | ||
| Global epidemiology of invasive meningococcal disease | Q37359946 | ||
| Solution conformation and flexibility of capsular polysaccharides from Neisseria meningitidis and glycoconjugates with the tetanus toxoid protein | Q37367010 | ||
| Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source | Q37531323 | ||
| Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence | Q38743826 | ||
| Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults | Q38905553 | ||
| Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial | Q39387871 | ||
| Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers | Q39764620 | ||
| Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial | Q40329667 | ||
| Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants: An Open, Randomized Trial. | Q40400436 | ||
| The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. | Q40461214 | ||
| Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children | Q40879602 | ||
| Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial | Q41075108 | ||
| Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age. | Q41160214 | ||
| Meningococcus group A vaccine in children three months to five years of age. Adverse reactions and immunogenicity related to endotoxin content and molecular weight of the polysaccharide | Q41390986 | ||
| Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales | Q41666578 | ||
| The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine | Q43874467 | ||
| Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile | Q44599973 | ||
| One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children. | Q50917553 | ||
| Immunogenicity and Safety of a Booster Dose of the 10-valent Pneumococcal Haemophilus Influenzae Protein D Conjugate Vaccine Coadministered With the Tetravalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine in Toddlers | Q56787267 | ||
| A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix® in subjects aged 11–17 years: An open, randomised, controlled trial | Q60469224 | ||
| Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age | Q83106446 | ||
| An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children | Q83656070 | ||
| Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using | Q87103662 | ||
| P433 | issue | 17 | |
| P921 | main subject | tetanus vaccine | Q5861101 |
| P304 | page(s) | 1881-1896 | |
| P577 | publication date | 2017-11-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACWY-TT; Nimenrix®): A Review | |
| P478 | volume | 77 |
Search more.